Publications of Matthias Knop
All genres
Journal Article (19)
2022
Journal Article
Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. ANNALS OF NEUROLOGY (2022)
2020
Journal Article
7 (5), e827 (2020)
Genetic determinants of the humoral immune response in MS. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2019
Journal Article
266 (2), pp. 386 - 397 (2019)
Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). JOURNAL OF NEUROLOGY 2016
Journal Article
2 (6), e1501678 (2016)
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. SCIENCE ADVANCES 2015
Journal Article
39 (8), pp. 601 - 608 (2015)
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. GENETIC EPIDEMIOLOGY
Journal Article
8 (404), p. ra119 - ra119 (2015)
Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Science signaling 2014
Journal Article
130 (1), pp. 46 - 52 (2014)
Interferon-1a reduces increased interleukin-16 levels in multiple sclerosis patients. ACTA NEUROLOGICA SCANDINAVICA 2012
Journal Article
259 (Suppl. 1), p. S13 - S13 (2012)
Methylprednisolone-regulated genes affecting multiple sclerosis pathogenesis. Journal of Neurology 2011
Journal Article
123 (6), pp. 400 - 406 (2011)
More CLEC16A gene variants associated with multiple sclerosis. Acta Neurologica Scandinavica 2010
Journal Article
227 (1-2), pp. 162 - 166 (2010)
Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. Journal of Neuroimmunology
Journal Article
81 (Suppl. 1), pp. 18 - 19 (2010)
USPIO-gestützte Charakterisierung der weißen Substanz bei MS. Nervenarzt
Journal Article
257 (Suppl. 1), pp. S218 - S219 (2010)
Modulation of interleukin-16 by interferon beta-1a treatment in patients with multiple sclerosis. Journal of Neurology 2009
Journal Article
80 (Suppl. 1), pp. 12 - 13 (2009)
Nachweis der Anreicherung von "Ultra Small Particles of Iron Oxide" in MS-Läsionen. Nervenarzt 2008
Journal Article
14 (Suppl. 1), p. S132 - S132 (2008)
Prohibitin: prohibiting inflammation in glatiramer acetate-treated multiple sclerosis patients? Multiple Sclerosis
Journal Article
255 (Suppl. 2), pp. 52 - 53 (2008)
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Journal of Neurology
Journal Article
9 (3), pp. 259 - 263 (2008)
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes and Immunity 2007
Journal Article
40 (5), p. 245 - 245 (2007)
Protein expression profiling of human glatiramer acetate (GA) and myelin basic protein (MBP) specific T cell lines from a multiple sclerosis (MS) patient and healthy donors. Pharmacopsychiatry
Journal Article
254 (Suppl. 3), pp. 189 - 190 (2007)
Protein expression profiling of human glatiramer acetate specific T cell lines from a multiple sclerosis patient and healthy donors. Journal of Neurology
Journal Article
254 (Suppl. 3), p. 73 - 73 (2007)
Human antigen specific T cell lines express neurturin, a member of the GDNF family ligands. Journal of Neurology Meeting Abstract (3)
2024
Meeting Abstract
30 (3), pp. 308 - 309. 40th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Copenhagen, DENMARK, September 18, 2024 - September 20, 2024. (2024)
Cytokines associated with disability progression over one year in a German monocentric MS cohort. In MULTIPLE SCLEROSIS JOURNAL,